NASHVILLE, Tenn., Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc.
(NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in
temperature-controlled supply chain solutions for the life sciences
industry, today announced that the Company will report financial
results for the fourth quarter and fiscal year ended December 31, 2020 on Monday, March 1, 2021 after U.S. markets
close.
In addition to the earnings release, a document titled "Cryoport
2020 Year in Review", providing a review of Cryoport's recent
financial and operational performance and a general business
update, will be issued at 4:05 pm EST on Monday, March 1, 2021. The document is designed
to be read by investors before the questions and answers conference
call and will be accessible at
http://ir.cryoport.com/events-and-presentations.
Cryoport management will host a conference call at 5:00 pm EST on March 1,
2021. The conference call will be in the format of a
questions and answers session and will address any queries
investors have regarding the Company's reported results.
Conference Call Information
|
Date:
|
March 1,
2021
|
|
Time:
|
5:00 p.m.
EST
|
|
Dial-in
numbers:
|
1-855-327-6837 (U.S.), 1-631-891-4304
(International)
|
|
Confirmation
code:
|
Request the "Cryoport
Call"
|
|
Live
webcast:
|
'Investor Relations'
section at www.cryoport.com or at this link. Please allow 10
minutes prior to the call to visit this site to download and
install any necessary audio software.
|
Questions and answers will be recorded and available
approximately three hours after completion of the live event on the
Investor Relations section of the Company's website at
www.cryoport.com for a limited time. To access the replay of the
questions and answers, please follow this link. A dial-in replay of
the call will also be available, to those interested, until
March 8, 2021. To access the replay,
dial +1 (844) 512-2921 (United
States) or +1 (412) 317-6671 (International) and enter
replay pin number: 10013100.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX) is redefining
temperature-controlled supply chain support for the life sciences
industry by continually broadening its platform of solutions and
services, serving the Biopharma, Reproductive Medicine, and Animal
Health markets. Through its family of companies, Cryoport Systems,
MVE Biological Solutions, CRYOPDP and CRYOGENE, Cryoport provides
strategic solutions that support the growing needs of these
markets.
Forward-Looking Statements
Statements in this press release which are not purely
historical, including statements regarding the Company's
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. It is important to note
that the Company's actual results could differ materially from
those in any such forward-looking statements. Factors that could
cause actual results to differ materially include, but are not
limited to, risks and uncertainties associated with the effect of
changing economic conditions, trends in the products markets,
variations in the Company's cash flow, market acceptance risks, and
technical development risks. The Company's business could be
affected by a number of other factors, including the risk factors
discussed in the Company's Securities and Exchange Commission
("SEC") reports including, but not limited to, the Company's
Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and any subsequent filings
with the SEC. The forward-looking statements contained in this
press release speak only as of the date hereof and the Company
cautions investors not to place undue reliance on these
forward-looking statements. Except as required by law, the Company
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cryoport-to-report-fourth-quarter-and-fiscal-year-2020-financial-results-on-march-1-2021-301235192.html
SOURCE Cryoport, Inc.